Novo Nordisk has launched Wegovy (semaglutide 2.4mg) in Malaysia, providing a new treatment for adults with obesity or overweight plus related health issues. This GLP-1 medication arrives as the country faces a mounting obesity crisis.
Malaysia's Growing Obesity Challenge
The National Health and Morbidity Survey (NHMS) 2023 shows that 54.4% of Malaysian adults are overweight or living with obesity. This epidemic underscores the need for effective interventions beyond traditional methods like gym memberships.
How Wegovy Works
Wegovy is a once-weekly injectable that mimics the natural gut hormone GLP-1. It targets brain areas to reduce hunger and cravings, promoting weight loss when paired with a reduced-calorie diet and increased physical activity.
Expert Insights on Obesity Treatment
Medical professionals praise the launch, viewing obesity as a complex disease influenced by biology, behavior, and environment.
"Obesity is a biological, behavioural, and environmental condition, and not simply the result of lack of discipline," said Professor Dr Rohana Abdul Ghani, President of the Malaysian Obesity Society.
She noted that stigma creates emotional barriers to weight management.
Endocrinologist Emeritus Professor Dr Chan Siew Pheng advocates a holistic approach: "By integrating medication with personalised dietary and lifestyle interventions, we can significantly improve patient outcomes." The body's metabolism often fights weight loss, making such combinations essential.
Obesity's Link to Heart Disease
Datuk Seri Dr Azhari Rosman, a senior consultant cardiologist, warns that obesity is a major risk factor for heart disease. Effective management is crucial for overall health.
Novo Nordisk's Commitment
Dr Praful Chakkarwar, General Manager of Novo Nordisk Malaysia, calls the launch a "pivotal moment." It supports local clinical research and public health initiatives to transform obesity care. Apps like Shotlee can help track weekly Wegovy doses for better adherence.
